Pharmacotherapy of intermittent claudication

Bibliography

• CAMERON HA, WALLER PC, RAMSAY LE: Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965-1985. BE j Clin. Pharmacol. (1988) 26:569–576.
   PubMed Web of Science ®Google Scholar
• MURABITO JM, D'AGOSTINO RB, SILBERSHATZ H, WILSON WF: Intermittent claudication. A risk profile for The Framingham Heart Study. Circulation (1997) 96:44–49.
   PubMedGoogle Scholar
• FONTAINE VR, KIM M, KICNY R: Die chirurgische Behandlung der peripheren Durchblutungsstörungen. Hely. Chic Acta. (1954) 5/6:499–533.
   Google Scholar
• GIROLAMI B, BERNARDI E, PRINS MH etal.: Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch. Intern. Med. (1999) 159:337–345.
   Google Scholar
• NEWMAN AB, SISCOVICK DS, MANOLIO TA: Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation (1993) 88:837–845.
   Google Scholar
• MANDELL GL: Cytokines, Phagocytes, and Pentoxifylline. j Cardiovasc. Pharmacol (1995) 25\(Suppl. 2): S20–S22.
   Google Scholar
• HOOD SC, MOHER D, BARBER GG: Management of intermittent claudication with pentoxyifylline: meta-analysis of randomised controlled trials. Can. Med. Assoc. J. (1996) 155:1053–1059.
   PubMed Web of Science ®Google Scholar
• CONE J, WANG S, TANDON N et al.: of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. j Cardiovasc. Pharmacol (1999) 34:497–504.
   PubMed Web of Science ®Google Scholar
• TANI T, UEHARA K, SUDO T et al: Cilostazol, a selective Type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats. Atherosclerosis (2000) 152:299–305.
   PubMed Web of Science ®Google Scholar
• LIU E FONG M, CONE J etal.: Inhibition of adenosine uptake and augmentation of ischaemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. Cardiovasc. Pharmacol (2000) 36:351–360.
   Google Scholar
• BRABER SL, FORBES WE MALLIKAARJUN S: Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. Clin. Pharmacokirietic. (1999) 37\(Supp1.2):1–11.
   Google Scholar
• MONEY SR, HERD JA, ISAACSOHN JL etal.: Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. j Vasc. Surg. (1998) 27:267–274.
   Google Scholar
• DAWSON DL, CUTLER BS, MEISSNER MH, STANDNESS DE, Jr.: Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomised, prospective, double-blind trial. Circulation (1998) 98:678–686.
   Google Scholar
• BEEBE HG, DAWSON DL, CUTLER BS etal.: A new pharmacological treatment for claudication: results of a randomised, mulitcenter trial. Arch. Intern. Med. (1999) 159:2041–2040.
   Google Scholar
• ELAM MB, HECKMAN J, CROUSE JR et al.: Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler. Thromb. Vasc. Biol. (1998) 18:1942–1947.
   PubMed Web of Science ®Google Scholar
• DAWSON DL, CUTLER BS, HIATT WR et al.: A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am. j Med. (2000) 109:523–530.
   PubMed Web of Science ®Google Scholar
• BARRADELL LB, BROGDEN RN: Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Drugs Aging (1996) 8:299–322.
   Google Scholar
• LE DEVEHAT C, T, MOSNIER M: Effect of naftidrofuryl on platelet aggregation in plasma form aspirin treated patients: an in vitro study. Clin. Hemorrheol ll/licrocirc. (2000) 22:197–204.
   PubMed Web of Science ®Google Scholar
• GIROLAMI B, BERNARDI E, PRINS MH et al.: Antithrombotic drugs in the primary medical management of intermittent claudication: a meta-analysis. Thromb. Haemost. (1999) 81:715–722.
   PubMed Web of Science ®Google Scholar
• KIEFFER E, BAHNINI A, MOUREN X, GAMAND S: A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Finding of the Naftidrofuryl Clinical ischaemia Study (NCIS). Int. *Vol. (2001) 20:58–65.
   Google Scholar
• SPENGEL F, BROWN TM, POTH J, LEHERT P: Naftidrofuryl can enhance the quality of life in patients with intermittent claudication. Vasa (1999) 28:207–212.
   PubMedGoogle Scholar
• HESS H, MIETASCHK A, DIECHSEL G:Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet (1985) 1:415–419.
   Google Scholar
• TONNESEN KH, ALBUQUERQUE P, BAITSCH G et al: Double-blind, controlled, multicenter study of indobufen versus placebo in patients with intermittent claudication. Int. Arigio. (1993) 12:371–377.
   Google Scholar
• ARCAN JC, BLANCHARD J, BOISSEL JP, DESTORS JM, PANAK E: Multiple double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Arigiology (1988) 39:802–811.
   PubMed Web of Science ®Google Scholar
• FAGER B: Long-term effects of ticlopidineon lower limb blood flow, ankle/arm index and symptoms in peripheral arteriosclerosis. A double-blind study. The STIMS Group in Lund. Swedish Ticlopidine Multicenter Study. Arigiology (1994) 45:777–788.
   Google Scholar
• BERGQVIST D, ALMGREN B, DICKINSON JP: Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: results from the Swedish Ticlopodine Multicentre Study (STIMS). Eur. Vase. Eridovasc. Surg. (1995) 10:69–76.
   PubMed Web of Science ®Google Scholar
• PARADISO-HARDY FL, ANGELO CM, CANCTOT KL, COHEN EA: Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality. CMAJ(2000) 163:1441–1448.
   PubMed Web of Science ®Google Scholar
• WALKER SR, TENNANT S, MACSWEENEY ST: A randomised, double-blind, placebo-controlled, crossover study to assess the immediate effect of sublingual glyceryl trinitrate on the ankle brachial pressure index, claudication, and maximum walking distance of patients with intermittent claudication. I Vase. Surg. (1998) 28:895–900.
   PubMed Web of Science ®Google Scholar
• BOGER RH, BODE-BOGER SM, THIELE W et al: Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation (1997) 95:2068–2074.
   PubMed Web of Science ®Google Scholar
• SCHELLONG SM, BOGER RH, BURCHERT W et al.: Dose-related effect of intravenous L-arginine on muscular blood flow of the calf in patients with peripheral vascular disease: a H2150 positron emission tomography study. Cliri. Sci. (Caleb) (1997) 93:159–165.
   PubMed Web of Science ®Google Scholar
• BOGER RH, BODE-BOGER SM, THIELE W et al.: Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J. Am. Coll. Cardiol. (1998) 32:1339–1344.
   Web of Science ®Google Scholar
• ANTONICELLI R, SARDINA M, SCOTTI A, BONIZZONI E, PACIARONE E: Randomised trial of the effects of low-dose calcium-heparin in patients with peripheral arterial disease and claudication. Italian CAP Study Group. Am.. (1999) 107:234–239.
   Google Scholar
• VIOLI F, MARUBINI E, COCCHERI S, NENCI GG: Improvement of walking distance by defibrotide in patients with intermittent claudication -results of a randomised, placebo-controlled study (the DICLIS study). Defibrotide Intermittent CLaudication Italian Study. Thromb. Haemost. (2000) 83:672–677.
   PubMed Web of Science ®Google Scholar
• DIEHM C, BALZER K, BISLER H et al:Efficacy of a new prostaglandin El regimen in outpatients with severe intermittent claudication: results of a multicenter placebo-controlled double-blind trial. _J. Vasc. Surg. (1997) 25:537–544.
   PubMed Web of Science ®Google Scholar
• MANGIAFICO RA, MESSINA R, ATTINA T et al.: Impact of a 4-week treatment with prostaglandin El on health-related quality of life of patients with intermittent claudication. Arigiology (2000) 51:441–449.
   PubMed Web of Science ®Google Scholar
• SCHEFFLER E GROSS J, MARKWIRTH T, MAIER J, SCHIEFFER H: Progress in the prostaglandin El-therapy of the intermittent claudication by means of bolus injections of LIPO-prostaglandin El (LIPO-PDG1). Eur. j Cliri. Pharmacy]. (1996) 51:235–239.
   PubMed Web of Science ®Google Scholar
• BELCH JJ, BELL PR, CREISSEN D etal.: Randomised, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin El prodrug, in patients with intermittent claudication. Circulation (1997) 95:2298–2302.
   Google Scholar
• LOOSEMORE TM, CHALMERS TC, DORMANDY JA: A meta-analysis of randomised placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. Int. Algol (1994) 13:133–142.
   Google Scholar
• LIEVRE M, AZOULAY S, LION L et al: Adose-effect study of beraprost sodium in intermittent claudication. j Cardiovasc. Pharmacy]. (1996) 27:788–793.
   PubMed Web of Science ®Google Scholar
• LIEVRE M, MORAND S, BESSE B, FIESSINGER JN, BOISSEL JP: Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomised, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation (2000) 102:426–431.
   Google Scholar
• BREVETTI G, CHIARIELLO M, FERULANO G et al.: Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation (1988) 77:767–773.
   PubMed Web of Science ®Google Scholar
• BREVETTI G, PERNA S, SABBA C et al: Superiority of L-propionlycarnitine vs. L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Eur. Heart J. (1992) 13:251–255.
   Google Scholar
• BREVETTI G, PERNA S, SABBA C, MARTONE VD, CONDORELLI M: Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. J. Am. Coll Cardiol (1995) 26:1411–1416.
   PubMed Web of Science ®Google Scholar
• BREVETTI G, PERNA S, SABBA C et al: Effect of propionyl-L-carnitine on quality of life in intermittent claudication. Am. Cardiol (1997) 79:777–780.
   PubMed Web of Science ®Google Scholar
• BREVETTI G, DIEHM C, LAMBERT D: European multicenter study on propionly-L-carnitine on intermittent claudication. Am. Coll Cardiol (1999) 34:1618–1624.
   PubMed Web of Science ®Google Scholar
• CLISSOLD SP, LYNCH S, SORKIN EM: Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peripheral and cerebral vascular diseases. Drugs (1987) 33:430–460.
   Google Scholar
• WALKER GA, MAC HANNAFORD JC: A meta-analysis of randomised, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication. Furidarn. Chu. Pharmacy]. (1995) 9:387–394.
   Google Scholar
• DE BACKER TL, VANDER STICHELE RH, WARIE HH, BOGAERT MG: Oral vasoactive medication in intermittent claudication: utile or futile? Eur. j Cliri. Pharmacy]. (2000) 56:199–206.
   Web of Science ®Google Scholar
• BAGGER JP, HELLIGSOE R, RANDSBAEK F, KIMROSE HH, JENSEN BS: Effect of verapamil in intermittent claudication. A randomised, double-blind, placebo-controlled, cross-over study after individual dose-response assessment. Circulation (1997) 95:411–414.
   Google Scholar
• MAS R, CASTANO G, ILLNAIT J et al: Effects of policosanol in patients with Type II hypercholesterolemia and additional coronary risk factors. Clin. Pharmacy]. Ther. (1999) 65:439–446.
   PubMed Web of Science ®Google Scholar
• ARRUZAZABALA ML, MAS R, MOLINA V etal.: Effect of policosanol on platelet aggregation in Type II hypercholesterolemic patients. Int. j Tissue. React. (1998) 20:119–124.
   Google Scholar
• CASTANO G, MAS R, ROCA J et al: A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication. Arigiology (1999) 50:123–130.
   PubMed Web of Science ®Google Scholar
• CASTANO G, MAS FERREIRO R, FERNANDEZ L, GAMEZ R, ILLNAIT J, FERNANDEZ C: A long-term study of policosanol in the treatment of intermittent claudication. Arigiology (2001) 52:115–125.
   PubMed Web of Science ®Google Scholar
• GRESELE P, MIGLIACCI R, DE SANTEG, NENCI GG: Effect of cloricromene on intermittent claudication. A randomised,-blind, placebo-controlled trial in patients treated with aspirin: effect on claudication distance and quality of life. CRAMPS Investigator Group. Cloricromene Randomised Arteriopathy Multicenter Prospective Study. Vasc. Med. (2000) 5:83–89.
   Google Scholar
• TORN WALL M, VIRTAMO J, HAUKKAJK et al.: Effect of alpha-tocopherol (vitamin E) and beta-carotene supplementation on the incidence of intermittent claudication in male smokers. Arteriarder. Throm. Vase. Biol. (1997) 17:3475–3480.
   PubMed Web of Science ®Google Scholar
• TORN WALL ME, VIRTAMO J, HAUKKA JK et al: The effect of alpha-tocopherol and beta-carotene supplementation on symptoms and progression of intermittent claudication in a controlled trial. Atherosclerosis (1999) 147:193–197.
   PubMed Web of Science ®Google Scholar
• YOSHIKAWA T, NAITO Y, KONDO M: Ginkgo biloba leaf extract: review of biological actions and clinical applications.. Reclax. Signal. (1999) 1:469–480.
   Google Scholar
• PETERS H, KIESER M, HOLSCHER U: Demonstration of the efficacy of ginkgo biloba special extract EGb 761 on intermittent claudication - a placebo-controlled, double-blind multicenter trial. Vasa (1998) 27:106–110.
   PubMedGoogle Scholar
• PITTLER MH, ERNST E: Ginkgo bilobaextract for the treatment of intermittent claudication: a meta-analysis of randomised trials. Am. J. Med. (2000) 108:276–281.
   PubMed Web of Science ®Google Scholar
• LAZAROUS DE UNGER EF, EPSTEIN SE et al.: Basic fibroblast growth factor in patients with intermittent claudication: results of a Phase I trial. ..J. Am. Coll. Cardiol (2000) 36:1239–1244.
   Google Scholar